Antisense & RNAi Therapeutics Market Report by Technology (RNA Interference, Antisense RNA), Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others), Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, and Others), and Region 2024-2032
The global antisense & RNAi therapeutics market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.25% during 2024-2032. The market is experiencing steady growth driven by the increasing prevalence of genetic and chronic diseases globally necessitates innovative treatments, supportive regulatory environments across major markets to expedite the approval and commercialization of new therapies, and continuous technological advancements in drug delivery systems.
Antisense & RNAi Therapeutics Market Analysis:
Technological advancements in drug delivery systems
In this market, one of the major drivers is the continuing developments of drug delivery methods. These technologies allow RNA molecules to be delivered to relevant cells cleanly and efficiently, in a pattern that avoids degradation and hence provided enhanced efficacy in terms of therapy. For example, lipid nanoparticles and conjugate technologies enabled the previously negligible cellular uptake and balance of antisense oligonucleotides or siRNA. It increases delivery while enhancing the degree of similarity in which therapeutics are suitable to target specific human material, which is critical in cancer, disorders, and viral infections, among other things. The antisense & RNAi therapeutics market forecast indicates that these treatments will gain substantial research attention and financial investment. For instance, Novartis acquired DTx Pharma in July 2023, which is a biotechnology company concentrating on short-interfering RNA therapy for neuroscience indications. Similarly, these acquisitions are creating a positive market outlook.
Increasing prevalence of genetic disorders and chronic diseases
The accelerating incidences of genetic and chronic diseases among the masses is significantly supporting the antisense & RNAi therapeutics market growth. Huntington’s, certain types of cancer, and a wide range of hereditary genetic conditions are just a few examples of prevalent illnesses with few efficient treatments, which create demand for antisense & RNAi therapeutics. Along with this, Antisense and RNAi treatment options provide a new avenue as candidate disease-predisposing genes’ repressors. On one hand, the new drugs have the best prospects of being included in clinical practice. On the other – by having the ability to target specific genes, they represent a new treatment modality for patients with conditions that are currently unmanageable using conventional pharmacological methods. This, in turn, generates a clear need for continued investment in new biopharmaceutical R&D projects.
Supportive regulatory environment for novel therapies
The antisense & RNAi therapeutics demand is impelled by the supportive regulatory environment. For instance, in October 2023, The Food and Drug Administration’s Office of Orphan Products Development announced the availability of funds for fiscal year (FY) 2024 to help underwrite the costs of conducting natural history studies on rare diseases and conditions. The stated goal of this RFA is “to advance scientific rigor and collaboration for the benefit of patients with rare diseases or conditions.” In addition, global health authorities, such as the FDA and EMA, are introducing faster review processes for any new therapies, inclusive of RNAi and antisense technology. Meanwhile, regulatory incentives like orphan drug status, accelerated approval, and priority review vouchers gain even more relevance since they give pharmaceutical companies even more incentive to put effort into the development of antisense and RNAi therapies.
Antisense & RNAi Therapeutics Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, route of administration and application.
Breakup by Technology:
The report has provided a detailed breakup and analysis of the market based on the technology. This includes RNA Interference(siRNA, and miRNA), and Antisense RNA. According to the antisense & RNAi therapeutics market report, Antisense RNA represented the largest segment.
Antisense RNA technology is the leader in the Antisense & RNAi Therapeutics market due to its mature methodology and the longest history of clinical application. Antisense RNA acts based on synthetic RNA molecules adhering to specific mRNA sequences, and it results in the blockade of target genes responsible for disease. In addition, the broadest possible range of applications from genetic pathologies to chronic diseases of various origins, including cancer, primarily has ensured its leader position. Apart from this, unlike other RNAi technologies, the leaders have already spent up to two years of widespread use, which allowed the investment of large resources in research and developing mechanisms of action and delivery. Moreover, some antisense therapeutic agents are already on the RNAi technology market with active FDA registration, which ultimately confirms their effectiveness and encourages further investment. All these factors contribute to ensuring a steady drill with the most significant share; even more, promising drugs already filed to proliferation can be observed in the antisense subfield. Thus, this technology leads the RNA based therapeutics market and lays the foundation for breakthroughs in this field.
Breakup by Route of Administration:
A detailed breakup and analysis of the market based on the route of administration have also been provided in the antisense & RNAi therapeutics market report. This includes intravenous route, subcutaneous route, intrathecal route, pulmonary delivery, intraperitoneal injection, and others. According to the report, pulmonary delivery accounted for the largest antisense & RNAi therapeutics market share.
In the Antisense & RNAi therapeutics market, pulmonary delivery has taken the lead in terms of administration channels. There are several justifications, including direct utilization in curing respiratory conditions, in which localized delivery significantly increases the effectiveness. Thus, the ability to access the lungs and carry therapeutic agents is effective in treating diseases such as respiratory syncytial virus and pulmonary arterial hypertension as well as directing to lung cancer. It enabled high concentration of the solution on the site of the disease, limited systemic, hence lower side effects, improved patient adherence, and the overall effectiveness of treatment. Moreover, innovative inhalers and solutions that allow efficient drug delivery to lung tissues are also an important aspect. Due to the increasing load, there is pressure to make therapy as effective and targeted as possible. Therefore, pulmonary delivery serves as a key development focus of the RNAi technology market and directs the overall investment and innovation quotas.
Breakup by Application:
Breakup by Region:
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for antisense & RNAi therapeutics.
North America is the largest regional segment in the Antisense & RNAi therapeutics market. This prominence is primarily due to the region's mature biotechnological and pharmaceutical research infrastructure. Additionally, unprecedented support from various national governments and other global health organizations has created a conducive environment for research and the advanced development required to progress antisense and RNAi therapy platforms. According to the antisense & RNAi therapeutics market analysis, the presence of several leading biotech and pharmaceutical companies in the region, which has created fierce competition and promoting innovation, has accelerated development opportunities as well as product launch. Additionally, North America’s proactive regulatory environment, the exceptional participation of the FDA, which has fast-tracked many RNA-based drugs for several genetic and chronic disease conditions, supports the RNA based therapeutics market. Moreover, the high prevalence of target diseases, including cancer and genetic disorders, in the region creates antisense & RNAi therapeutics demand. Thus, North America leads the Antisense & RNAi Therapeutics market, as a dominant player in technology development and also as the primary market for RNA-based therapeutic products.
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the antisense & RNAi therapeutics industry include:
The major players in the market are increasingly involved in research and development to diversify their genetic therapy portfolios. They are actively engaging in strategic partnerships, taking over small biotech companies, or collaborating with academic institutions and R&D centers to capitalize on emerging and disruptive technologies and fast-track drug development. In confluence with this, considering the high costs and development risks, companies make significant investments in clinical trials to guarantee their effectiveness and safety in a wider applications portfolio, especially in AlNM diseases. Collaboration with the regulatory bodies enhances the companies’ competitive performance and guides them along the way to bring new drugs faster. This initiative is vital for creating competitive advantages and a positive antisense & RNAi therapeutics market outlook.
Antisense & RNAi Therapeutics Market News:
1. How big is the global antisense & RNAi therapeutics market?
2. What is the expected growth rate of the global antisense & RNAi therapeutics market during 2024-2032?
3. What are the key factors driving the global antisense & RNAi therapeutics market?
4. What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
5. What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
6. What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
7. What are the key regions in the global antisense & RNAi therapeutics market?
8. Who are the key players/companies in the global antisense & RNAi therapeutics market?
Antisense & RNAi Therapeutics Market Analysis:
- Major Market Drivers: The market is driven by powerful technological drivers such as rapid advancements in drug delivery systems, which increased therapeutic impact on cells and targeting specificity, and a high incidence of genetic disorders and chronic diseases, which requires the use of cutting-edge therapeutic modalities.
- Key Market Trends: One of the major antisense & RNAi therapeutics industry trends is its tight association with the personalization of medicine based on unique genetic profiles and aimed at improving patient outcomes.
- Geographical Trends: According to the antisense & RNAi therapeutics market analysis, North America dominates the market for Antisense & RNAi Therapeutics due to its excellent healthcare infrastructure, high healthcare spending, and friendly regulatory environment.
- Competitive Landscape: This is a dynamic market with a pool of traditional drug market players such as top pharmaceutical companies and innovators that have established themselves. The competitive space will have to determine the battle for patents of owned technologies, achieving the green light from the regulatory authorities, and making new collaborations.
- Challenges and Opportunities: The antisense & RNAi therapeutics market research report shows that the industry’s major challenge is the high cost and complexity of developing and managing RNAi and antisense-based therapies. The latter is also an opportunity since it will transform the sector into loci of innovation and low-cost drug discovery resulting in breakthroughs in untreated genetic diseases.
Technological advancements in drug delivery systems
In this market, one of the major drivers is the continuing developments of drug delivery methods. These technologies allow RNA molecules to be delivered to relevant cells cleanly and efficiently, in a pattern that avoids degradation and hence provided enhanced efficacy in terms of therapy. For example, lipid nanoparticles and conjugate technologies enabled the previously negligible cellular uptake and balance of antisense oligonucleotides or siRNA. It increases delivery while enhancing the degree of similarity in which therapeutics are suitable to target specific human material, which is critical in cancer, disorders, and viral infections, among other things. The antisense & RNAi therapeutics market forecast indicates that these treatments will gain substantial research attention and financial investment. For instance, Novartis acquired DTx Pharma in July 2023, which is a biotechnology company concentrating on short-interfering RNA therapy for neuroscience indications. Similarly, these acquisitions are creating a positive market outlook.
Increasing prevalence of genetic disorders and chronic diseases
The accelerating incidences of genetic and chronic diseases among the masses is significantly supporting the antisense & RNAi therapeutics market growth. Huntington’s, certain types of cancer, and a wide range of hereditary genetic conditions are just a few examples of prevalent illnesses with few efficient treatments, which create demand for antisense & RNAi therapeutics. Along with this, Antisense and RNAi treatment options provide a new avenue as candidate disease-predisposing genes’ repressors. On one hand, the new drugs have the best prospects of being included in clinical practice. On the other – by having the ability to target specific genes, they represent a new treatment modality for patients with conditions that are currently unmanageable using conventional pharmacological methods. This, in turn, generates a clear need for continued investment in new biopharmaceutical R&D projects.
Supportive regulatory environment for novel therapies
The antisense & RNAi therapeutics demand is impelled by the supportive regulatory environment. For instance, in October 2023, The Food and Drug Administration’s Office of Orphan Products Development announced the availability of funds for fiscal year (FY) 2024 to help underwrite the costs of conducting natural history studies on rare diseases and conditions. The stated goal of this RFA is “to advance scientific rigor and collaboration for the benefit of patients with rare diseases or conditions.” In addition, global health authorities, such as the FDA and EMA, are introducing faster review processes for any new therapies, inclusive of RNAi and antisense technology. Meanwhile, regulatory incentives like orphan drug status, accelerated approval, and priority review vouchers gain even more relevance since they give pharmaceutical companies even more incentive to put effort into the development of antisense and RNAi therapies.
Antisense & RNAi Therapeutics Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, route of administration and application.
Breakup by Technology:
- RNA Interference
- siRNA
- miRNA
- Antisense RNA
The report has provided a detailed breakup and analysis of the market based on the technology. This includes RNA Interference(siRNA, and miRNA), and Antisense RNA. According to the antisense & RNAi therapeutics market report, Antisense RNA represented the largest segment.
Antisense RNA technology is the leader in the Antisense & RNAi Therapeutics market due to its mature methodology and the longest history of clinical application. Antisense RNA acts based on synthetic RNA molecules adhering to specific mRNA sequences, and it results in the blockade of target genes responsible for disease. In addition, the broadest possible range of applications from genetic pathologies to chronic diseases of various origins, including cancer, primarily has ensured its leader position. Apart from this, unlike other RNAi technologies, the leaders have already spent up to two years of widespread use, which allowed the investment of large resources in research and developing mechanisms of action and delivery. Moreover, some antisense therapeutic agents are already on the RNAi technology market with active FDA registration, which ultimately confirms their effectiveness and encourages further investment. All these factors contribute to ensuring a steady drill with the most significant share; even more, promising drugs already filed to proliferation can be observed in the antisense subfield. Thus, this technology leads the RNA based therapeutics market and lays the foundation for breakthroughs in this field.
Breakup by Route of Administration:
- Intravenous Route
- Subcutaneous Route
- Intrathecal Route
- Pulmonary Delivery
- Intraperitoneal Injection
- Others
A detailed breakup and analysis of the market based on the route of administration have also been provided in the antisense & RNAi therapeutics market report. This includes intravenous route, subcutaneous route, intrathecal route, pulmonary delivery, intraperitoneal injection, and others. According to the report, pulmonary delivery accounted for the largest antisense & RNAi therapeutics market share.
In the Antisense & RNAi therapeutics market, pulmonary delivery has taken the lead in terms of administration channels. There are several justifications, including direct utilization in curing respiratory conditions, in which localized delivery significantly increases the effectiveness. Thus, the ability to access the lungs and carry therapeutic agents is effective in treating diseases such as respiratory syncytial virus and pulmonary arterial hypertension as well as directing to lung cancer. It enabled high concentration of the solution on the site of the disease, limited systemic, hence lower side effects, improved patient adherence, and the overall effectiveness of treatment. Moreover, innovative inhalers and solutions that allow efficient drug delivery to lung tissues are also an important aspect. Due to the increasing load, there is pressure to make therapy as effective and targeted as possible. Therefore, pulmonary delivery serves as a key development focus of the RNAi technology market and directs the overall investment and innovation quotas.
Breakup by Application:
- Oncology
- Cardiovascular Diseases (CVDs)
- Respiratory Disorders
- Renal Diseases
- Neurodegenerative Disorders
- Genetic Disorders
- Infectious Diseases
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for antisense & RNAi therapeutics.
North America is the largest regional segment in the Antisense & RNAi therapeutics market. This prominence is primarily due to the region's mature biotechnological and pharmaceutical research infrastructure. Additionally, unprecedented support from various national governments and other global health organizations has created a conducive environment for research and the advanced development required to progress antisense and RNAi therapy platforms. According to the antisense & RNAi therapeutics market analysis, the presence of several leading biotech and pharmaceutical companies in the region, which has created fierce competition and promoting innovation, has accelerated development opportunities as well as product launch. Additionally, North America’s proactive regulatory environment, the exceptional participation of the FDA, which has fast-tracked many RNA-based drugs for several genetic and chronic disease conditions, supports the RNA based therapeutics market. Moreover, the high prevalence of target diseases, including cancer and genetic disorders, in the region creates antisense & RNAi therapeutics demand. Thus, North America leads the Antisense & RNAi Therapeutics market, as a dominant player in technology development and also as the primary market for RNA-based therapeutic products.
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the antisense & RNAi therapeutics industry include:
- Alnylam Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- Benitec Biopharma Ltd.
- Bio-Path Holdings Inc.
- Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
- Ionis Pharmaceuticals Inc.
- OliX Pharmaceuticals Inc.
- Phio Pharmaceuticals Corp.
- Sarepta Therapeutics Inc.
- Silence Therapeutics
- Sirnaomics Inc.
The major players in the market are increasingly involved in research and development to diversify their genetic therapy portfolios. They are actively engaging in strategic partnerships, taking over small biotech companies, or collaborating with academic institutions and R&D centers to capitalize on emerging and disruptive technologies and fast-track drug development. In confluence with this, considering the high costs and development risks, companies make significant investments in clinical trials to guarantee their effectiveness and safety in a wider applications portfolio, especially in AlNM diseases. Collaboration with the regulatory bodies enhances the companies’ competitive performance and guides them along the way to bring new drugs faster. This initiative is vital for creating competitive advantages and a positive antisense & RNAi therapeutics market outlook.
Antisense & RNAi Therapeutics Market News:
- April 08, 2024: OliX Pharmaceuticals Inc., a leading developer of RNA interfering therapeutics in the treatment area of severe diseases including fibro-inflammatory and metabolic diseases, disclosed that the Company has gotten approval from the Alfred Human Research Ethics Committee to commence the Phase 1 clinical trial of drug candidate OLX75016 (candidate of OLX702A for NASH treatment).
- June 21, 2023: Arbutus Biopharma Corporation provided the first data from the empirical study on RNA interference therapy, nucleos(t)ide analogue (NA), and pegylated interferon alfa-2a therapy in patients with chronic hepatitis B virus at the EASL Conference 2023.
1. How big is the global antisense & RNAi therapeutics market?
2. What is the expected growth rate of the global antisense & RNAi therapeutics market during 2024-2032?
3. What are the key factors driving the global antisense & RNAi therapeutics market?
4. What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
5. What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
6. What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
7. What are the key regions in the global antisense & RNAi therapeutics market?
8. Who are the key players/companies in the global antisense & RNAi therapeutics market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY TECHNOLOGY
6.1 RNA Interference
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 siRNA
6.1.2.2 miRNA
6.1.3 Market Forecast
6.2 Antisense RNA
6.2.1 Market Trends
6.2.2 Market Forecast
7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION
7.1 Intravenous Route
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Subcutaneous Route
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Intrathecal Route
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Pulmonary Delivery
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Intraperitoneal Injection
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 MARKET BREAKUP BY APPLICATION
8.1 Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cardiovascular Diseases (CVDs)
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Respiratory Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Renal Diseases
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Neurodegenerative Disorders
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Genetic Disorders
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Infectious Diseases
8.7.1 Market Trends
8.7.2 Market Forecast
8.8 Others
8.8.1 Market Trends
8.8.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Alnylam Pharmaceuticals Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Arbutus Biopharma Corporation
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Arrowhead Pharmaceuticals Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.4 Benitec Biopharma Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Bio-Path Holdings Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Ionis Pharmaceuticals Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 OliX Pharmaceuticals Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Phio Pharmaceuticals Corp.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.10 Sarepta Therapeutics Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Silence Therapeutics
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Sirnaomics Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY TECHNOLOGY
6.1 RNA Interference
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 siRNA
6.1.2.2 miRNA
6.1.3 Market Forecast
6.2 Antisense RNA
6.2.1 Market Trends
6.2.2 Market Forecast
7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION
7.1 Intravenous Route
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Subcutaneous Route
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Intrathecal Route
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Pulmonary Delivery
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Intraperitoneal Injection
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 MARKET BREAKUP BY APPLICATION
8.1 Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cardiovascular Diseases (CVDs)
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Respiratory Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Renal Diseases
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Neurodegenerative Disorders
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Genetic Disorders
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Infectious Diseases
8.7.1 Market Trends
8.7.2 Market Forecast
8.8 Others
8.8.1 Market Trends
8.8.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Alnylam Pharmaceuticals Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Arbutus Biopharma Corporation
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Arrowhead Pharmaceuticals Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.4 Benitec Biopharma Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Bio-Path Holdings Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Ionis Pharmaceuticals Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 OliX Pharmaceuticals Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Phio Pharmaceuticals Corp.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.10 Sarepta Therapeutics Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Silence Therapeutics
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Sirnaomics Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
LIST OF TABLES
Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players
Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players
LIST OF FIGURES
Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2023
Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2023
Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2023
Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2023
Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2023
Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis
Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2023
Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2023
Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2023
Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2023
Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2023
Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis
